Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | FPR2 | P25090 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | FPR3 | P25089 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19563375 | 1.00 | MEN1 (0.50) | MEN1KMT2ANPC1RAB9AFPR2 | |
| SCHEMBL19563286 | 0.88 | MEN1 (0.45) | MEN1KMT2ANPC1RAB9AFPR2 | |
| SCHEMBL16748864 | 0.88 | MEN1 (0.45) | MEN1KMT2ANPC1RAB9AFPR2 | |
| SCHEMBL19547843 | 0.88 | MEN1 (0.48) | MEN1KMT2ANPC1RAB9AFPR2 | |
| SCHEMBL16742470 | 0.84 | FPR2 (0.45) | MEN1KMT2ANPC1RAB9AFPR2 | |
| SCHEMBL19547828 | 0.83 | MEN1 (0.49) | MEN1KMT2ANPC1RAB9AFPR2 | |
| SCHEMBL19547830 | 0.83 | MEN1 (0.49) | MEN1KMT2ANPC1RAB9AFPR2 | |
| SCHEMBL19563266 | 0.82 | FPR2 (0.58) | MEN1KMT2ANPC1RAB9AFPR2 | |
| SCHEMBL16742493 | 0.82 | FPR2 (0.58) | MEN1KMT2ANPC1RAB9AFPR2 | |
| SCHEMBL16742509 | 0.81 | MEN1 (0.60) | MEN1KMT2ANPC1RAB9AFPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3071548-B1 | PHENYLCARBAMATE DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2017-11-08 | — | — | EP | claimed |
| US-9926264-B2 | Phenylcarbamate derivatives as formyl peptide receptor modulators | ALLERGAN, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-9926264-B2 | Phenylcarbamate derivatives as formyl peptide receptor modulators | ALLERGAN, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-9926264-B2 | Phenylcarbamate derivatives as formyl peptide receptor modulators | ALLERGAN, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| EP-3071548-B1 | PHENYLCARBAMATE DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20160272581-A1 | PHENYLCARBAMATE DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160272581-A1 | PHENYLCARBAMATE DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160272581-A1 | PHENYLCARBAMATE DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20150190351-A1 | Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof | Annji Pharmaceutical Co., Ltd. (TW) | 2015-07-09 | — | — | US | disclosed |
| WO-2015077451-A1 | PHENYLCARBAMATE DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272581-A1 | PHENYLCARBAMATE DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS | FPR2, FPR1, FPR3 | MEN1 4109/4885KMT2A 4480/4885NPC1 1890/4885 |
| US-20150190351-A1 | Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof | AR, BRCA1, CYP17A1 | MEN1 2785/4885KMT2A 2312/4885NPC1 3814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.